Led strategic definition of the Medical Affairs strategy, structure and processes to materialise the repositioning of the company with the acquisition established vaccines and the launch of commercial operations, supporting new asset development and market expansion
Built a team of recognised key, coordinating with regulators (FDA & EMA) and public-health organisations (WHO, UNICEF, NIH, HERA, GAVI, African CDC, CEPI) to ensure efficient vaccine distribution, data generation and data-driven communication
Oversaw worldwide launch of a new vaccine
Transformed Clinical Development to streamline product launch readiness and overseen Phase I-IV studies for several vaccines
Created the Department of Epidemiology, driving studies that led to label updates
Redefined the Department of Medical Writing
Transformed the Global Clinical Safety & Pharmacovigilance function
Prioritised pipeline projects to guide corporate growth and strategic goals